Clinical trial
Study of Adalimumab Treatment for Induction and Maintenance of Clinical…
NCT00409617 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00409617 |
|---|---|
| Title | Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease |
| Official title | A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Biological |
| Interventions | adalimumab |
| Enrollment | 945 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Dec 11, 2006 |
| Last update posted | Oct 10, 2011 |
| Countries | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Norway, Portugal and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: